DeWolf WC - Search Results

1

A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.

Luo Y, Szilvasi A, Chen X, DeWolf WC, O'Donnell MA. Luo Y, et al. Among authors: dewolf wc. Clin Diagn Lab Immunol. 1996 Nov;3(6):761-8. doi: 10.1128/cdli.3.6.761-768.1996. Clin Diagn Lab Immunol. 1996. PMID: 8914772 Free PMC article.

2

IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.

Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. Luo Y, et al. Among authors: dewolf wc. J Immunol. 1999 Feb 15;162(4):2399-405. J Immunol. 1999. PMID: 9973521

3

Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.

Luo Y, Chen X, Han R, Chorev M, Dewolf WC, O'Donnell MA. Luo Y, et al. Among authors: dewolf wc. J Urol. 1999 Oct;162(4):1519-26. J Urol. 1999. PMID: 10492248

4

Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes.

O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, DeWolf WC. O'Donnell MA, et al. Among authors: dewolf wc. Infect Immun. 1994 Jun;62(6):2508-14. doi: 10.1128/iai.62.6.2508-2514.1994. Infect Immun. 1994. PMID: 8188376 Free PMC article.

5

Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant.

Maranchie JK, Bouyounes BT, Zhang PL, O'Donnell MA, Summerhayes IC, DeWolf WC. Maranchie JK, et al. Among authors: dewolf wc. J Urol. 2000 Mar;163(3):748-51. J Urol. 2000. PMID: 10687969

6

Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse.

O'Donnell MA, DeWolf WC. O'Donnell MA, et al. Among authors: dewolf wc. Surg Oncol Clin N Am. 1995 Apr;4(2):189-202. Surg Oncol Clin N Am. 1995. PMID: 7796280 Review.

7

Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed.

O'Donnell MA, Krohn J, DeWolf WC. O'Donnell MA, et al. Among authors: dewolf wc. J Urol. 2001 Oct;166(4):1300-4, discussion 1304-5. J Urol. 2001. PMID: 11547062

8

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.

Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: dewolf wc. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. J Urol. 2020. PMID: 31821066

9

Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.

Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, Crump T, Wang J, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Steinberg RL, et al. Among authors: dewolf wc. Urol Oncol. 2022 Jan;40(1):9.e1-9.e7. doi: 10.1016/j.urolonc.2021.03.024. Epub 2021 Jun 4. Urol Oncol. 2022. PMID: 34092482

10

Synchronous adenocarcinoma and transitional cell carcinoma of the bladder associated with augmentation: case report and review of the literature.

Gregoire M, Kantoff P, DeWolf WC. Gregoire M, et al. Among authors: dewolf wc. J Urol. 1993 Jan;149(1):115-8. doi: 10.1016/s0022-5347(17)36016-0. J Urol. 1993. PMID: 8417189 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters